(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.
PharmaMar has requested the process of re-examination for Aplidin® from the EMA
Please login to join discussion
POPULAR NEWS
-
Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission
-
New Study Reveals the Science Behind Exercise and Weight Loss
-
New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases
-
Revolutionizing Optimization: Deep Learning for Complex Systems